Histone deacetylase inhibitors: A new class of potential therapeutic agents for cancer treatment

Clinical Cancer Research

Volumn 8, Issue 3, 2002, Pages 662-664

  Richon, Victoria M ^a   O'Brien, James P ^a  

^a Aton Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 N ACETYLDINALINE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; DEPSIPEPTIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; SHORT CHAIN FATTY ACID; TRICHOSTATIN A; VALPROIC ACID;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA HISTONE INTERACTION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LEUKEMIA; LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN MODIFICATION; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; T CELL LYMPHOMA;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS; DEPSIPEPTIDES; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; PEPTIDES, CYCLIC;

EID: 0036304760     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Histone deacetylases, transcriptional control, and cancer
2. Histone deacetylases and cancer: Causes and therapies
3. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms
4. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report
5. Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
6. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen
7. Chronic oral administration of CI-994: A phase 1 study
8. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
9. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
10. Regulation of activity of the transcription factor GATA-1 by acetylation
11. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
12. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y
13. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase
14. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases
15. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells
16. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice
17. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity
18. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation
19. Effects of trichostatins on differentiation of murine erythroleukemia cells
20. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
21. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation
22. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells
23. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells
24. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects
25. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
26. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
27. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines
28. Epigenetic regulation of gelsolin expression in human breast cancer cells
29. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells
30. Histone acetylation and disease
31. Transcription therapy for cancer
32. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression
33. Role of the histone deacetylase complex in acute promyelocytic leukaemia
34. Distinct interactions of PML-RARα and PLZ-FRARα with co-repressors determine differential responses to RA in APL
35. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia